Contineum Therapeutics (CTNM) Share-based Compensation (2023 - 2026)

Contineum Therapeutics' Share-based Compensation history runs 4 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 48.81% year-over-year to $3.8 million in Q1 2026; TTM through Mar 2026 was $9.1 million, a 40.05% increase from a year earlier, with the FY2025 full-year figure at $10.0 million, down 51.51% from the prior year.
• Share-based Compensation climbed to $3.8 million in Q1 2026 per CTNM's latest filing, from $2.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $23.1 million in Q3 2025 and bottomed at -$1.4 million in Q4 2023.
• The 4-year median for Share-based Compensation is $768000.0 (2024), against an average of $2.7 million.
• Across the five-year window, Share-based Compensation jumped 114450.0% in 2024 and tumbled 55.5% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at -$1.4 million in 2023, then jumped by 174.2% to $1.1 million in 2024, then surged by 132.61% to $2.5 million in 2025, then surged by 54.03% to $3.8 million in 2026.
• Per Business Quant, the three latest CTNM Share-based Compensation figures stand at $3.8 million (Q1 2026), $2.5 million (Q4 2025), and $23.1 million (Q3 2025).